Meta
joel topf
NephJC is a non-profit organization

NephJC needs your help. Time to open your wallet and help keep the lights on at NephJC HQ. Also score some pretty fly NephJC fleece, hats and tote bags. (Yeah, we know that there has never been a “fly” tote bag. Work with us.

NephJC is a non-profit organization
Meta
joel topf
Get ready for the 2019 NephJC Kidneys

The NephJC Kidneys return for the fourth year. Time for #NephTwitter to nominate their favs.

Get ready for the 2019 NephJC Kidneys
Background
Matt Sparks
Can We Stop MUC-1 From Mucking Up the Kidney

Some cases of ADTKD are due to mutations of the MUC-1 gene, one mutation is a frame shift mutation that results in a premature stop codon. which results in accumulation of the abnormally short, and toxic protein MUC-1 fs . The researchers found a small protein, BRD4780, that reroute MUC-1fs to lysosomes, preventing proteinopathy and possibly altering the natural history of the disease.

Can We Stop MUC-1 From Mucking Up the Kidney
Background
joel topf
Pathology of Calcific Uremic Arteriolopathy

This week is a joint #DermJC and #NephJC. We will discuss two articles - here is the summary of the larger case series, from Vandana Niyyar.

Pathology of Calcific Uremic Arteriolopathy
Background
joel topf
Should Race be Replaced? Reconsidering the eGFR ...

This week, we will discuss a perspective peice looking at the use of race in the eGFR formulas routinely used in the hospital. #NephJC chat. 

Should Race be Replaced? Reconsidering the eGFR Equations.

jama

Kidney Transplant & Race and Ethnicity: Things are Getting Better - Or Are They?

Kidney Transplant & Race and Ethnicity: Things are Getting Better - Or Are They?

This week, we will discuss the JAMA paper on disparities in living donor kidney transplant *rates* across race/ethnicities. There is a parallel paper from the UK, which shows somewhat similar findings. Join us Feb 6 and 7 to discuss on #NephJC!

IgA Nephropathy: Testing Steroids Again

IgA Nephropathy: Testing Steroids Again

Stop-IgAN suggested steroids may not be useful in patients with intermediate range proteinuria. Now, in a different population with more proteinuria, TESTING finds a mixed result: some benfit + more adverse events. Should we keep on TESTING?